INS365 Ophthalmic Solution

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Keratoconjunctivitis Sicca

Conditions

Keratoconjunctivitis Sicca

Trial Timeline

Apr 1, 2002 → Mar 1, 2003

NCT ID

NCT00037661

About INS365 Ophthalmic Solution

INS365 Ophthalmic Solution is a phase 3 stage product being developed by Merck for Keratoconjunctivitis Sicca. The current trial status is completed. This product is registered under clinical trial identifier NCT00037661. Target conditions include Keratoconjunctivitis Sicca.

What happened to similar drugs?

1 of 8 similar drugs in Keratoconjunctivitis Sicca were approved

Approved (1) Terminated (0) Active (7)

✅Cyclosporine A + DexamethasoneNovartisApproved

🔄FK506Astellas PharmaPhase 3

🔄FK506 + placeboAstellas PharmaPhase 3

🔄OTX-101 0.09%Sun PharmaceuticalPhase 3

🔄cyclosporine + vehicle of OTX-101Sun PharmaceuticalPhase 3

🔄RebamipideNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00037661	Phase 3	Completed	Apr 1, 2002	Mar 1, 2003	Keratoconjunctivitis Sicca

Competing Products

15 competing products in Keratoconjunctivitis Sicca

See all competitors

Product	Company	Stage	Hype Score
FK506	Astellas Pharma	Phase 3	40
FK506 + placebo	Astellas Pharma	Phase 3	40
OTX-101 0.09%	Sun Pharmaceutical	Phase 3	40
OTX-101 0.05% + OTX-101 0.09% + Vehicle	Sun Pharmaceutical	Phase 2/3	38
cyclosporine + vehicle of OTX-101	Sun Pharmaceutical	Phase 3	40
Pimecrolimus + Vehicle	Novartis	Phase 2	35
Cyclosporine A + Dexamethasone	Novartis	Approved	43
Rebamipide	Novartis	Phase 3	40
Rebamipide	Novartis	Phase 3	40
Tasocitinib + Tasocitinib + vehicle for Tasocitinib	Pfizer	Phase 2	27
Dupilumab	Regeneron Pharmaceuticals	Phase 2	31
R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% + R348 Ophthalmic Solution, 1.0% + Placebo	Rigel Pharmaceuticals	Phase 1	23
R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% + Placebo	Rigel Pharmaceuticals	Phase 2	29
CF101	Can Fite Biopharma	Phase 3	30
CF101 + Placebo	Can Fite Biopharma	Phase 2	25